AKT1 and diffuse large B-cell lymphoma: According to the study results of Kapoor et al. [48], Ibrutinib-resistant DLBCL (IB-R) cell lines showed downregulation of FOXO3a and PTEN levels in the nuclei and activation of AKT signaling.